Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
PLAINSBORO, N.J., Feb. 26, 2016 -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it will present at the following conference in March:
- At 4:00PM ET on Tuesday, March 1, 2016, Mr. Mark Augusti, President – Orthopedics & Tissue Technologies, will present at the Canaccord 11th Annual Musculoskeletal Conference in Orlando, FL. This presentation will not be webcast.
- At 2:15PM ET on Monday, March 7, 2016, Mr. Glenn Coleman, Chief Financial Officer, will present at the Raymond James & Associates’ 37th Annual Institutional Investors Conference in Orlando, FL. This presentation will not be webcast.
- At 4:50PM ET on Tuesday, March 15, 2016, Mr. Coleman, will present at the Barclays Global Healthcare Conference in Miami, FL. This presentation will be webcast.
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for caregivers, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading regenerative technologies, in specialty surgical solutions and orthopedics and tissue technologies. For more information, please visit www.integralife.com
Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2014 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts: Integra LifeSciences Holdings Corporation Investor Relations: Angela Steinway (609) 936-2268 [email protected] Michael Beaulieu (609) 750-2827 [email protected]
